Study of new drug combo for untreated mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mantle cell lymphoma that has not been treated before (except local radiation or a very short course of steroids).
- You need to have at least one tumor or lymph node that can be measured on a scan.
- Your organs (kidneys, liver) must be working well enough, and your blood counts (such as neutrophils, hemoglobin, platelets) should be in a safe range.
- You cannot have lymphoma that has spread to your brain or spinal cord.
- You cannot have a serious active infection, recent major surgery, or a history of certain heart conditions (like heart failure, recent heart attack, or uncontrolled arrhythmia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This study tests a combination of a targeted pill (zanubrutinib) with standard chemotherapy (R-CHOP/R-DHAP) for people newly diagnosed with mantle cell lymphoma. The goal is to see how well this approach works and to potentially improve treatment outcomes for this type of lymphoma.
This trial tests a combination of three medications (zanubrutinib, obinutuzumab, and sonrotoclax) for people with mantle cell lymphoma, a type of blood cancer. The goal is to see if this combination is safe and effective, and it may be an option for people who are older or have health issues that make a stem cell transplant too risky.
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
This study tests a combination of chemotherapy and targeted therapy as the first treatment for older adults with mantle cell lymphoma. The treatment is guided by regular scans and blood tests (PET-CT and MRD) to see how well it's working and to adjust it if needed.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.